

December 19, 2017



Poxel Announces its Financial Calendar for 2018

Poxel Announces its Financial Calendar for 2018

Lyon, France, December 19, 2017 – POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, announces its schedule for the publication of financial information for 2018.

Event	Date*
2017 Fourth Financial Update	January 22, 2018
2017 Full Year Statement	March 22, 2018
2018 First Quarter Financial Update	April 23, 2018
2018 Second Quarter Financial Update	July 10, 2018
2018 First Half Statement	September 19, 2018
2018 Third Quarter Financial Update	October 16, 2018
2018 Fourth Quarter Financial Update	January 22, 2019

*Subject to modification

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes. We have successfully completed our Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., EU and Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)

Contacts

Poxel SA

Jonae R. Barnes
Senior Vice President, Investor Relations and Public Relation
jonae.barnes@poxelpharma.com
+1 617 818 2985

Investor relations / Media - EU/US

Trophic Communications
Gretchen Schweitzer or Stephanie May
may@trophic.eu
+49 89 23887734 or +49 171 855682

Investor relations / Media - France

NewCap
Florent Alba/Nicolas Mérieau
poxel@newcap.fr
+33 1 44 71 98 55